Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lawsuit Seeking FDA Triclosan Action Stays Alive On Appeal

This article was originally published in The Tan Sheet

Executive Summary

A court ruling allowing an advocacy group to move forward in its suit against FDA could pave the way for future litigation intended to force the agency to complete delayed regulations.

You may also be interested in...



California DTSC’s Draft Work Plan Includes Personal Care, But Few Surprises

“Beauty, personal care and hygiene” as one of seven product categories could be priorities in the next round of product selections in California’s Safer Consumer Products program. PCPC welcomes the direction DTSC appears to be taking toward more active industry engagement over the next three years.

California DTSC’s Draft Work Plan Includes Personal Care, But Few Surprises

“Beauty, personal care and hygiene” as one of seven product categories could be priorities in the next round of product selections in California’s Safer Consumer Products program. PCPC welcomes the direction DTSC appears to be taking toward more active industry engagement over the next three years.

FDA’s Top Agenda Maker: Commissioner, Congress – Or The Courts?

Agency chief counsel says continued priority-setting through lawsuits eventually may affect public health, while professor says FDA discretion not to act is at stake in some cases.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106306

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel